Disc Medicine, Inc. (IRON)
Nasdaq · Healthcare · Biotechnology
$63.33−1.83%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.4B
- 52-week range
- $40.00 – $99.50
- 52-week change
- −4.98%
- EPS (trailing)
- −$6.58
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$212M
- Diluted EPS
- −$6.01
- Free cash flow
- −$181M
From the company’s annual report on SEC EDGAR.
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Headquarters: Watertown, United States · 165 employees · discmedicine.com